Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy These 5 FTSE 100 Shares? – Aggreko plc (AGK), Experian plc (EXPN)

Page 1 of 2

I have recently been evaluating the investment cases for a multitude of FTSE 100 companies.

Although Britain’s foremost share index has risen 6.8% so far in 2013, I believe many London-listed stocks still have much further to run, while conversely others appear overdue for a correction. So how do the following five stocks weigh up?

I reckon beverage can manufacturer Rexam PLC (LON:REX) is an excellent pick for any stock investor based on both its growth potential and generous dividend policy.

Rexam announced within its results this week that volumes rose 6% in 2012, pushing revenue 2% higher to £4.3 billion and underlying pre-tax profit 1% higher to £418 million. The company said new contract wins in North America, coupled with growth in Europe and South America, helped to drive the performance.

City brokers expect earnings per share to advance 11% in 2013 and 9% in 2014, up from the 5% increase punched last year. Rexam is striding higher on the back of a rising international footprint, particularly in emerging markets, and steady manufacturing capacity hikes.

Moreover, the firm’s plump dividends are also expected to rise over the medium term. Last year’s 3.5% yield was in line with the current FTSE 100 average, although that 3.5% figure is forecast to accelerate to 3.7% and 4.1% over the next two years.

Experian plc (LON:EXPN)
I’d bet on credit-services provider Experian to surge higher as it continues to expand strongly in both traditional and developing geographies.

The company’s interims released in January revealed third-quarter organic growth of 7%, driven by the rapid progress the group is making in emerging markets.

Revenues in South America, for example, leapt 11% during October, November, and December. I believe that rising affluence levels in these new, juicy end-markets, coupled with bubbly M&A activity across the globe, should underpin future growth.

Following an expected 1% rise in earnings per share for the year ending March 2013, growth is forecast to hit solid double-digit territory in coming years — a 19% increase next year is projected to rise a further 11% in 2015, according to brokers.

I do not believe a P/E ratio of 21.3 for March 2013 can be considered ‘nosebleed’ territory given the potential for very decent earnings growth. Furthermore, the P/E reading is projected to drop to 17.8 and 16 in 2014 and 2015 respectively.

Vedanta Resources plc (LON:VED)
I believe that Vedanta is on a stronger footing than many of its mining sector peers, as a significant ramp-up in oil production and lead-zinc metal output in coming years looks set to drive top-line growth higher.

Total oil output jumped 21% in quarter three, Vedanta announced last month, to 205,014 barrels of oil equivalent per day, as operations at the company’s Rajasthan field shot higher to 169,977 barrels a day.

The company is aiming to hike Rajasthan output to 200,000-215,000 barrels a day by March 2014, with a view to increasing it to 300,000 barrels thereafter. On the metals front, Vedanta is seeking to increase lead-zinc production to 1.2 million tonnes within the next six years.

Earnings per share is set to edge 2% higher in the year ending March 2013, City analysts predict, before shooting 77% higher the following year and then jumping an additional 25% in 2015.

Accelerating growth is set to drive Vedanta’s P/E ratio much lower in coming years — a value of 13.4 for 2013 is forecast to collapse to 7.6 in 2014 and 6.3 in 2015.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!